alexa In vitro and In vivo Assessment of Pi3Kγ Inhibitors for Anti-Inflammatory Indications: Challenges of Selectivity over Pi3Kα | OMICS International | Abstract
ISSN: 2161-105X

Journal of Pulmonary & Respiratory Medicine
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

In vitro and In vivo Assessment of Pi3Kγ Inhibitors for Anti-Inflammatory Indications: Challenges of Selectivity over Pi3Kα

David Lamb*, Graham Lunn, Mark O’Reilly, Cheryl Butler and Iain Kilty

Pfizer Global Research and Development, Sandwich Laboratories, United Kingdom

*Corresponding Author:
David Lamb
Pfizer Global Research and Development
Sandwich Laboratories, Ramsgate Road
Sandwich, Kent, CT13 9NJ, United Kingdom
Tel: +49-7351-54141403
Fax: 49-7351- 5498674
E-mail: [email protected]

Received date: March 16, 2013; Accepted date: September 24, 2013; Published date: September 26, 2013

Citation: Lamb D, Lunn G, O’Reilly M, Butler C, Kilty I (2013) In vitro and In vivo Assessment of Pi3K? Inhibitors for Anti-Inflammatory Indications: Challenges of Selectivity over Pi3Ka. J Pulm Respir Med 3:157. doi: 10.4172/2161-105X.1000157

Copyright: © 2013 Lamb D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Class 1 PI3Ks are a growing area of interest as pharmacological targets across a number of disease mechanisms. We have assessed the feasibility of developing selective PI3Kgamma inhibitors based upon the ATP-binding hinge site. Following full file screening, 8800 analogues representing 25 chemotypes were further analysed across a panel of PI3K enzymes and cellular assays. Despite this we did not identify a series of compounds which possessed all required criteria of potency, selectivity, metabolic stability and solubility. We profiled the best 3 compounds in vivo to assess their anti-inflammatory efficacy versus PI3Kalpha driven perturbations in glucose/insulin homeostasis. Each compound dose-dependently inhibited LPS elicited pulmonary neutrophilia in rat with a marginal therapeutic index over a subsequent increase in glucose and insulin elevation. In our opinion these studies provide no evidence of a divergence from enzyme selectivity to an in vivo therapeutic index over insulin and glucose perturbations and therefore there is no evidence to suggest ATP competitive hinge binding site PI3Kgamma inhibitors will afford sufficient in vivo TI worthy of clinical progression for inflammatory indications.

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version